Zimmer Biomet Reports Strong Q1 2026 Earnings with Strategic Growth
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 28 2026
0mins
Should l Buy ZBH?
Source: seekingalpha
- Sales Growth Highlight: Zimmer Biomet reported net sales of $2.087 billion for Q1, reflecting a 2.9% year-over-year increase, with U.S. knee sales growing by 2.2% and over 20% growth in partial knee sales, indicating strong market performance.
- Earnings Guidance Raised: The company raised its 2026 adjusted EPS guidance to $8.40 to $8.55 from the previous $8.30 to $8.45, while also increasing free cash flow growth expectations to 9% to 11%, reflecting management's confidence in future performance.
- Management Changes: Dr. Jonathan Vigdorchik has joined as Chief Science, Technology and Medical Affairs Officer, while CFO Suky announced his departure, with Paul Stellato stepping in as Interim CFO, which may impact the company's financial strategy and execution.
- Market Challenges and Opportunities: Despite pressures from brand rationalization in knee products and policy uncertainties, management remains optimistic about maintaining sales growth guidance of 2.5% to 4.5% for 2026, demonstrating resilience and adaptability during the transition period.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ZBH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ZBH
Wall Street analysts forecast ZBH stock price to rise
18 Analyst Rating
4 Buy
11 Hold
3 Sell
Hold
Current: 82.330
Low
88.00
Averages
100.47
High
120.00
Current: 82.330
Low
88.00
Averages
100.47
High
120.00
About ZBH
Zimmer Biomet Holdings, Inc. is a global medical technology company. It designs, manufactures and markets orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; CMFT; surgical products; and a suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence. Its segments include Americas, EMEA, and Asia Pacific. Its products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. Its knee brands include the Persona Knee, NexGen Knee Implants, Vanguard Knee and Oxford Partial Knee. Its hip brands include the Taperloc Hip System, Avenir Complete Hip System, Arcos Modular Hip System and G7 Acetabular System. It also focused on a suite of orthopedic robotics, enabling solutions and analytics to address the needs of surgeons pre-, intra- and post-operatively. Its portfolio features imageless robotics through its ROSA Robotics platform.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Stryker Misses Q1 Profit and Revenue Estimates Amid Cyberattack
- Profit Outlook Maintained: Stryker reiterated its full-year adjusted profit outlook of $14.90 to $15.10 per share, despite missing first-quarter profit and revenue estimates, demonstrating resilience amid soft market demand.
- Revenue Decline: The company reported total revenue of $6.02 billion for the first quarter, falling short of analysts' expectations of $6.35 billion, primarily impacted by weakened demand for complex surgical devices, reflecting challenges in the medical device market.
- Segment Performance: Sales in the medical surgery and neurotechnology segment rose 5% to $3.21 billion but missed the $3.83 billion forecast, while the orthopedics segment saw a 6.3% increase to $2.81 billion, exceeding the $2.51 billion expectation, indicating varied performance across business lines.
- Cyberattack Impact: Stryker faced a cyberattack in March attributed to the Iranian-linked group Handala, causing operational disruptions and limited system access; although the company could not verify related social media claims, this incident likely added pressure to its business operations.
See More
Zimmer Biomet Stock Rating and Price Target
- Rating Overview: Zimmer Biomet (ZBH) holds an average rating of hold, indicating a cautious market sentiment regarding its future performance and suggesting that investors view the company's growth potential with neutrality.
- Price Target Analysis: Analysts have set an average price target of $98.24 for Zimmer Biomet, a figure that could influence investor buying decisions, particularly in the current market environment.
- Market Reaction: Despite the hold rating, market reactions to Zimmer Biomet may be influenced by the overall performance of the medical device industry, prompting investors to monitor industry trends for more informed investment choices.
- Investment Strategy Advice: Given the current rating and price target, investors should exercise caution when considering investments in Zimmer Biomet, weighing the balance between its long-term growth potential and associated market risks.
See More
Zimmer Biomet Reports Strong Q1 Earnings, Raises Guidance
- Earnings Beat: Zimmer Biomet reported strong Q1 earnings that exceeded market expectations, indicating the company's sustained growth potential in the medical device sector, which is likely to have a positive impact on its stock price.
- Guidance Raised: The company raised its future earnings guidance, reflecting an optimistic outlook on market demand, a move that could bolster investor confidence and attract more capital inflows.
- Mixed Analyst Views: Despite the strong performance, analysts maintain mixed views on the stock, with some expressing caution regarding the company's future growth potential, which may affect overall market sentiment towards its shares.
- Market Reaction Monitoring: As earnings and guidance improve, the market's reaction to Zimmer Biomet will be crucial, and investors should closely monitor subsequent stock price movements and changes in analyst ratings.
See More
Zimmer Biomet Reports Strong Q1 2026 Earnings with Strategic Growth
- Sales Growth Highlight: Zimmer Biomet reported net sales of $2.087 billion for Q1, reflecting a 2.9% year-over-year increase, with U.S. knee sales growing by 2.2% and over 20% growth in partial knee sales, indicating strong market performance.
- Earnings Guidance Raised: The company raised its 2026 adjusted EPS guidance to $8.40 to $8.55 from the previous $8.30 to $8.45, while also increasing free cash flow growth expectations to 9% to 11%, reflecting management's confidence in future performance.
- Management Changes: Dr. Jonathan Vigdorchik has joined as Chief Science, Technology and Medical Affairs Officer, while CFO Suky announced his departure, with Paul Stellato stepping in as Interim CFO, which may impact the company's financial strategy and execution.
- Market Challenges and Opportunities: Despite pressures from brand rationalization in knee products and policy uncertainties, management remains optimistic about maintaining sales growth guidance of 2.5% to 4.5% for 2026, demonstrating resilience and adaptability during the transition period.
See More
Zimmer Biomet CFO Departure Leads to Stock Decline
- Executive Departure Impact: Zimmer Biomet announced that CFO Suketu Upadhyay will leave on April 28, leading to a ~6% stock decline on Tuesday, potentially marking its largest single-day drop since November, reflecting market unease over executive changes.
- Financial Performance Beats Expectations: The company reported Q1 adjusted EPS of $2.09 and sales of $2.1 billion, exceeding consensus estimates by $20 million and $0.23, indicating strong performance in the medical device sector.
- Product Line Sales Performance: While knee product sales reached $828.6 million, slightly below the $832.3 million forecast, hip product sales of $524 million showed ~6% YoY growth, surpassing expectations and demonstrating the company's competitive strength in specific product lines.
- Stable Outlook: Zimmer Biomet maintained its revenue growth forecast for 2026 at 2.5% to 4.5% and raised its adjusted EPS outlook to $8.40 - $8.55, reflecting confidence in future performance despite potential short-term uncertainties from executive changes.
See More
Zimmer Biomet CFO Departure Triggers Stock Decline
- CFO Departure Impact: Zimmer Biomet announced the departure of CFO Suketu Upadhyay effective April 28, leading to a ~6% drop in stock price, potentially marking its largest single-day decline since November, reflecting market sensitivity to executive changes.
- Financial Performance Beats Expectations: The company reported Q1 adjusted EPS of $2.09 on $2.1 billion in sales, exceeding consensus estimates by $20 million and $0.23, indicating sustained growth potential in the medical device sector.
- Product Sales Mixed Results: While knee product sales reached $828.6 million with ~5% YoY growth, missing analyst projections of $832.3 million, hip sales hit $524 million with ~6% YoY growth, surpassing the $517.7 million forecast, suggesting uneven performance across product lines.
- Stable Outlook: Zimmer Biomet maintained its revenue growth forecast for 2026 at 2.5% to 4.5% and raised its adjusted EPS outlook to $8.40 - $8.55, demonstrating confidence in future performance despite uncertainties in the overall market.
See More
Stryker Misses Q1 Profit and Revenue Estimates Amid Cyberattack
- Profit Outlook Maintained: Stryker reiterated its full-year adjusted profit outlook of $14.90 to $15.10 per share, despite missing first-quarter profit and revenue estimates, demonstrating resilience amid soft market demand.
- Revenue Decline: The company reported total revenue of $6.02 billion for the first quarter, falling short of analysts' expectations of $6.35 billion, primarily impacted by weakened demand for complex surgical devices, reflecting challenges in the medical device market.
- Segment Performance: Sales in the medical surgery and neurotechnology segment rose 5% to $3.21 billion but missed the $3.83 billion forecast, while the orthopedics segment saw a 6.3% increase to $2.81 billion, exceeding the $2.51 billion expectation, indicating varied performance across business lines.
- Cyberattack Impact: Stryker faced a cyberattack in March attributed to the Iranian-linked group Handala, causing operational disruptions and limited system access; although the company could not verify related social media claims, this incident likely added pressure to its business operations.
See More
Zimmer Biomet Stock Rating and Price Target
- Rating Overview: Zimmer Biomet (ZBH) holds an average rating of hold, indicating a cautious market sentiment regarding its future performance and suggesting that investors view the company's growth potential with neutrality.
- Price Target Analysis: Analysts have set an average price target of $98.24 for Zimmer Biomet, a figure that could influence investor buying decisions, particularly in the current market environment.
- Market Reaction: Despite the hold rating, market reactions to Zimmer Biomet may be influenced by the overall performance of the medical device industry, prompting investors to monitor industry trends for more informed investment choices.
- Investment Strategy Advice: Given the current rating and price target, investors should exercise caution when considering investments in Zimmer Biomet, weighing the balance between its long-term growth potential and associated market risks.
See More
Zimmer Biomet Reports Strong Q1 Earnings, Raises Guidance
- Earnings Beat: Zimmer Biomet reported strong Q1 earnings that exceeded market expectations, indicating the company's sustained growth potential in the medical device sector, which is likely to have a positive impact on its stock price.
- Guidance Raised: The company raised its future earnings guidance, reflecting an optimistic outlook on market demand, a move that could bolster investor confidence and attract more capital inflows.
- Mixed Analyst Views: Despite the strong performance, analysts maintain mixed views on the stock, with some expressing caution regarding the company's future growth potential, which may affect overall market sentiment towards its shares.
- Market Reaction Monitoring: As earnings and guidance improve, the market's reaction to Zimmer Biomet will be crucial, and investors should closely monitor subsequent stock price movements and changes in analyst ratings.
See More
Zimmer Biomet Reports Strong Q1 2026 Earnings with Strategic Growth
- Sales Growth Highlight: Zimmer Biomet reported net sales of $2.087 billion for Q1, reflecting a 2.9% year-over-year increase, with U.S. knee sales growing by 2.2% and over 20% growth in partial knee sales, indicating strong market performance.
- Earnings Guidance Raised: The company raised its 2026 adjusted EPS guidance to $8.40 to $8.55 from the previous $8.30 to $8.45, while also increasing free cash flow growth expectations to 9% to 11%, reflecting management's confidence in future performance.
- Management Changes: Dr. Jonathan Vigdorchik has joined as Chief Science, Technology and Medical Affairs Officer, while CFO Suky announced his departure, with Paul Stellato stepping in as Interim CFO, which may impact the company's financial strategy and execution.
- Market Challenges and Opportunities: Despite pressures from brand rationalization in knee products and policy uncertainties, management remains optimistic about maintaining sales growth guidance of 2.5% to 4.5% for 2026, demonstrating resilience and adaptability during the transition period.
See More
Zimmer Biomet CFO Departure Leads to Stock Decline
- Executive Departure Impact: Zimmer Biomet announced that CFO Suketu Upadhyay will leave on April 28, leading to a ~6% stock decline on Tuesday, potentially marking its largest single-day drop since November, reflecting market unease over executive changes.
- Financial Performance Beats Expectations: The company reported Q1 adjusted EPS of $2.09 and sales of $2.1 billion, exceeding consensus estimates by $20 million and $0.23, indicating strong performance in the medical device sector.
- Product Line Sales Performance: While knee product sales reached $828.6 million, slightly below the $832.3 million forecast, hip product sales of $524 million showed ~6% YoY growth, surpassing expectations and demonstrating the company's competitive strength in specific product lines.
- Stable Outlook: Zimmer Biomet maintained its revenue growth forecast for 2026 at 2.5% to 4.5% and raised its adjusted EPS outlook to $8.40 - $8.55, reflecting confidence in future performance despite potential short-term uncertainties from executive changes.
See More
Zimmer Biomet CFO Departure Triggers Stock Decline
- CFO Departure Impact: Zimmer Biomet announced the departure of CFO Suketu Upadhyay effective April 28, leading to a ~6% drop in stock price, potentially marking its largest single-day decline since November, reflecting market sensitivity to executive changes.
- Financial Performance Beats Expectations: The company reported Q1 adjusted EPS of $2.09 on $2.1 billion in sales, exceeding consensus estimates by $20 million and $0.23, indicating sustained growth potential in the medical device sector.
- Product Sales Mixed Results: While knee product sales reached $828.6 million with ~5% YoY growth, missing analyst projections of $832.3 million, hip sales hit $524 million with ~6% YoY growth, surpassing the $517.7 million forecast, suggesting uneven performance across product lines.
- Stable Outlook: Zimmer Biomet maintained its revenue growth forecast for 2026 at 2.5% to 4.5% and raised its adjusted EPS outlook to $8.40 - $8.55, demonstrating confidence in future performance despite uncertainties in the overall market.
See More
